The estimated Net Worth of Richard S Levy is at least $4.23 Milhão dollars as of 5 June 2024. Richard Levy owns over 4,373 units of Madrigal Pharmaceuticals Inc stock worth over $3,005,001 and over the last 16 years he sold MDGL stock worth over $559,130. In addition, he makes $662,500 as Independent Director at Madrigal Pharmaceuticals Inc.
Richard has made over 44 trades of the Madrigal Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of MDGL stock worth $1,018,909 on 5 June 2024.
The largest trade he's ever made was exercising 231,096 units of Madrigal Pharmaceuticals Inc stock on 13 February 2014 worth over $2,029,023. On average, Richard trades about 11,032 units every 63 days since 2009. As of 5 June 2024 he still owns at least 12,897 units of Madrigal Pharmaceuticals Inc stock.
You can see the complete history of Richard Levy stock trades at the bottom of the page.
Dr. Richard S. Levy M.D. serves as Independent Director of the Company. Dr. Levy has served on Madrigal’s board of directors since August of 2016. Dr. Levy also serves on the board of directors of Artara Therapeutics, Inc., Kodiak Sciences Inc., and Kiniksa Pharmaceuticals, Ltd., each a publicly-held pharmaceutical company. Dr. Levy previously served on the board of Aquinox Pharmaceuticals, Inc. Previously, from December 2016 to May 2019, Dr. Levy was a part-time Senior Advisor for Baker Bros. Advisors, L.P., a firm that primarily manages long-term investment funds focused on publicly traded life sciences companies. Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016, and as Senior Vice President of Drug Development at Incyte from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly-held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis, and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy has more than 25 years’ experience in the pharmaceutical and biotechnology industries through his prior positions at Incyte, Celgene, DuPont Pharmaceuticals and Novartis, has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of M
As the Independent Director of Madrigal Pharmaceuticals Inc, the total compensation of Richard Levy at Madrigal Pharmaceuticals Inc is $662,500. There are 11 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.
Richard Levy is 62, he's been the Independent Director of Madrigal Pharmaceuticals Inc since 2016. There are 8 older and 9 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.
Richard's mailing address filed with the SEC is 1200 PAGE MILL ROAD, , PALO ALTO, CA, 94304.
Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman, eBros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.
madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include: